Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 7/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | CTSV | O60911 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17509882 | 0.82 | GPR84 (0.42) | GPR84MPOXDHPDE7APDE7B | |
| SCHEMBL4118331 | 0.79 | TNKS2 (0.46) | GPR84TNKS2KDM4EDAO | |
| SCHEMBL8936160 | 0.79 | GRIN2D (0.43) | ARTNKS2KDM4ECYP1A2TP53 | |
| SCHEMBL17509867 | 0.75 | AR (0.46) | ARTNKS2TNKSKDM4ECYP1A2 | |
| SCHEMBL29792700 | 0.74 | LMNA (0.47) | GPR84ARCYP1A2SMN1; SMN2 | |
| SCHEMBL13326518 | 0.74 | LMNA (0.47) | GPR84ARCYP1A2SMN1; SMN2 | |
| SCHEMBL17509834 | 0.73 | KDM4E (0.44) | GPR84ARCTSVCTSLKDM4E | |
| SCHEMBL29770446 | 0.73 | ALDH1A1 (0.59) | TNKS2KDM4ECYP1A2SMN1; SMN2 | |
| SCHEMBL4045859 | 0.73 | ALDH1A1 (0.59) | TNKS2KDM4ECYP1A2SMN1; SMN2 | |
| SCHEMBL28402937 | 0.72 | LMNA (0.60) | GPR84ARKDM4ECYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257651-A1 | NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2016-09-08 | — | — | US | disclosed |
| EP-2987787-A1 | NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY | Juntendo Educational Foundation (JP) | 2016-02-24 | — | — | EP | disclosed |
| WO-2007117778-A9 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS INC (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1986747-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | Kalypsys, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | NOS2, NOS1, NQO2 | GPR84 3142/4885MPO 177/4885XDH 7/4885 |
| US-20160257651-A1 | NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY | SLC11A2, RELA, NFKBIA | GPR84 4258/4885MPO 14/4885XDH 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.